Musculoskeletal manifestations of lysosomal storage disorders

Annals of the Rheumatic Diseases

Volumn 68, Issue 11, 2009, Pages 1659-1665

  Aldenhoven, M ^a   Sakkers, R J B ^a   Boelens, J ^a   De Koning, T J ^a   Wulffraat, N M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME;

ENZYME REPLACEMENT; HUMAN; LYSOSOME STORAGE DISEASE; MEDICAL SPECIALIST; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; SYMPTOM; DIFFERENTIAL DIAGNOSIS; LIPIDOSIS; MUCOPOLYSACCHARIDOSIS;

DIAGNOSIS, DIFFERENTIAL; HUMANS; LYSOSOMAL STORAGE DISEASES; MUCOPOLYSACCHARIDOSES; MUSCULOSKELETAL DISEASES; SPHINGOLIPIDOSES;

EID: 70449719317     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.095315     Document Type: Review

References (82)

1. Vijay S, Wraith JE. Clinical presentation and follow-up of patients with the attenuated phenotype of mucopolysaccharidosis type I. Acta Paediatr 2005;94:872-877 (Pubitemid 41044770)
2. Pastores GM, Meere PA. Musculoskeletal complications associated with lysosomal storage disorders: Gaucher disease and Hurler-Scheie syndrome (mucopolysaccharidosis type I). Curr Opin Rheumatol 2005;17:70-78
3. Cimaz R, Vijay S, Haase C, et al. Attenuated type I mucopolysaccharidosis in the differential diagnosis of juvenile idiopathic arthritis: a series of 13 patients with Scheie syndrome. Clin Exp Rheumatol 2006;24:196-202. (Pubitemid 43826873)
4. Melikoglu MA, Kocabas H, Sezer I, et al. Legg-Perthes disease-like joint involvement and diagnosis delay in Scheie syndrome: a case report. Clin Rheumatol 2007;26:1937-1939 (Pubitemid 47516981)
5. Manger B, Mengel E, Schaefer RM. Rheumatologic aspects of lysosomal storage diseases. Clin Rheumatol 2007;26:335-341 (Pubitemid 46486963)
6. Wagner L. Fellow clinical challenge. Pediatr Rheumatol Online J 2003;1:188-192
7. Paira SO, Roverano S, Iribas JL, et al. Joint manifestations of Fabry's disease. Clin Rheumatol 1992;11:562-565
8. Weizman Z, Tennenbaum A, Yatziv S. Interphalangeal joint involvement in Gaucher's disease, type I, resembling juvenile rheumatoid arthritis. Arthritis Rheum 1982;25:706-707 (Pubitemid 12078987)
9. Meikle PJ, Hopwood JJ, Clague AE, et al. Prevalence of lysosomal storage disorders. JAMA 1999;281:249-254
10. Poorthuis BJ, Wevers RA, Kleijer WJ, et al. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 1999;105:151-156 (Pubitemid 29396979)
11. Schmidt H, Ullrich K, von Lengerke HJ, et al. Radiological findings in patients with mucopolysaccharidosis I H/S (Hurler-Scheie syndrome). Pediatr Radiol 1987;17:409-414 (Pubitemid 17097248)
12. Chen SJ, Li YW, Wang TR, et al. Bony changes in common mucopolysaccharidoses. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi 1996;37:178-184
13. Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver C, Beaudet A, Sly W, et al, eds. The metabolic and molecular basis of inherited disease. 8th ed. New York: McGraw-Hill, 2001:3421-3452
14. Muenzer J. The mucopolysaccharidoses: a heterogeneous group of disorders with variable pediatric presentations. J Pediatr 2004;144:S27-34. (Pubitemid 38591272)
15. Fisher RC, Horner RL, Wood VE. The hand in mucopolysaccharide disorders. Clin Orthop Relat Res 1974;104:191-199
16. Haddad FS, Jones DH, Vellodi A, et al. Carpal tunnel syndrome in the mucopolysaccharidoses and mucolipidoses. J Bone Joint Surg Br 1997;79:576-582 (Pubitemid 27346112)
17. Van Meir N, De Smet L. Carpal tunnel syndrome in children. Acta Orthop Belg 2003;69:387-395
18. Wraith JE, Alani SM. Carpal tunnel syndrome in the mucopolysaccharidoses and related disorders. Arch Dis Child 1990;65:962-963 (Pubitemid 20304934)
19. Van Heest AE, House J, Krivit W, et al. Surgical treatment of carpal tunnel syndrome and trigger digits in children with mucopolysaccharide storage disorders. J Hand Surg [Am] 1998;23:236-243 (Pubitemid 29098769)
20. Weisstein JS, Delgado E, Steinbach LS, et al. Musculoskeletal manifestations of Hurler syndrome: long-term follow-up after bone marrow transplantation. J Pediatr Orthop 2004;24:97-101. (Pubitemid 38030056)
21. MacDougal B, Weeks PM, Wray RC Jr. Median nerve compression and trigger finger in the mucopolysaccharidoses and related diseases. Plast Reconstr Surg 1977;59:260-263 (Pubitemid 8032797)
22. Maurer K, Fenske A, Samii M. Carpal tunnel syndrome combined with trigger finger in early childhood. J Neurol Neurosurg Psychiatry 1980;43:1148.
23. Matsui Y, Kawabata H, Nakayama M, et al. Scheie syndrome (MPS-IS) presented as bilateral trigger thumb. Pediatr Int 2003;45:91-92 (Pubitemid 36523567)
24. Silveri CP, Kaplan FS, Fallon MD, et al. Hurler syndrome with special reference to histologic abnormalities of the growth plate. Clin Orthop Relat Res 1991;269:305-311
25. Simonaro CM, Haskins ME, Schuchman EH. Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: a possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses. Lab Invest 2001;81:1319-1328
26. Simonaro CM, D'Angelo M, Haskins ME, et al. Joint and bone disease in mucopolysaccharidoses VI and VII: identification of new therapeutic targets and biomarkers using animal models. Pediatr Res 2005;57:701-707 (Pubitemid 40578042)
27. Simonaro CM, D'Angelo M, He X, et al. Mechanism of glycosaminoglycan- mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases. Am J Pathol 2008;172:112-122 (Pubitemid 351186373)
28. Lotz M, Hashimoto S, Kuhn K. Mechanisms of chondrocyte apoptosis. Osteoarthritis Cartilage 1999;7:389-391
29. Tetlow LC, Adlam DJ, Woolley DE. Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage: associations with degenerative changes. Arthritis Rheum 2001;44:585-594
30. Yoshihara Y, Nakamura H, Obata K, et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann Rheum Dis 2000;59:455-461 (Pubitemid 30395603)
31. Hirai Y, Migita K, Honda S, et al. Effects of nitric oxide on matrix metalloproteinase-2 production by rheumatoid synovial cells. Life Sci 2001;68:913-920 (Pubitemid 32168066)
32. de Vries-Bouwstra JK, Goekoop-Ruiterman YP, Wesoly J, et al. Ex vivo interleukin 1 receptor antagonist production on lipopolysaccharide stimulation is associated with rheumatoid arthritis and with joint damage. Ann Rheum Dis 2007;66:1033-1037 (Pubitemid 47122315)
33. Ortutay Z, Polgar A, Gomor B, et al. Synovial fluid exoglycosidases are predictors of rheumatoid arthritis and are effective in cartilage glycosaminoglycan depletion. Arthritis Rheum 2003;48:2163-2172 (Pubitemid 36959196)
34. Field RE, Buchanan JA, Copplemans MG, et al. Bone-marrow transplantation in Hurler's syndrome. Effect on skeletal development. J Bone Joint Surg Br 1994;76:975-981
35. Wraith JE. The first 5 years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I. Expert Opin Pharmacother 2005;6:489-506. (Pubitemid 40521085)
36. Odunusi E, Peters C, Krivit W, et al. Genu valgum deformity in Hurler syndrome after hematopoietic stem cell transplantation: correction by surgical intervention. J Pediatr Orthop 1999;19:270-274 (Pubitemid 29129636)
37. Masterson EL, Murphy PG, O'Meara A, et al. Hip dysplasia in Hurler's syndrome: orthopaedic management after bone marrow transplantation. J Pediatr Orthop 1996;16:731-733 (Pubitemid 26353391)
38. Cleary MA, Wraith JE. The presenting features of mucopolysaccharidosis type IH (Hurler syndrome). Acta Paediatr 1995;84:337-339
39. Spada M, Pagliardini S, Yasuda M, et al. High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet 2006;79:31-40. (Pubitemid 43927374)
40. Mehta A, Ricci R, Widmer U, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 2004;34:236-242 (Pubitemid 38406640)
41. Masson C, Cisse I, Simon V, et al. Fabry disease: a review. Joint Bone Spine 2004;71:381-383
42. Clarke JT. Narrative review: Fabry disease. Ann Intern Med 2007;146:425-433
43. Germain DP, Benistan K, Boutouyrie P, et al. Osteopenia and osteoporosis: previously unrecognized manifestations of Fabry disease. Clin Genet 2005;68:93-95 (Pubitemid 40867545)
44. Whybra C, Kampmann C, Willers I, et al. Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes. J Inherit Metab Dis 2001;24:715-724 (Pubitemid 34023880)
45. Grabowski GA, Andria G, Baldellou A, et al. Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements. Eur J Pediatr 2004;163:58-66. (Pubitemid 38223386)
46. Charrow J, Andersson HC, Kaplan P, et al. The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med 2000;160:2835-2843 (Pubitemid 30743862)
47. Kaplan P, Andersson HC, Kacena KA, et al. The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis. Arch Pediatr Adolesc Med 2006;160:603-608 (Pubitemid 43854401)
48. Wenstrup RJ, Roca-Espiau M, Weinreb NJ, et al. Skeletal aspects of Gaucher disease: a review. Br J Radiol 2002;75:A2-12. (Pubitemid 34654095)
49. Mankin HJ, Rosenthal DI, Xavier R. Gaucher disease. New approaches to an ancient disease. J Bone Joint Surg Am 2001;83:748-762
50. Pastores GM, Patel MJ, Firooznia H. Bone and joint complications related to Gaucher disease. Curr Rheumatol Rep 2000;2:175-180
51. Desnick R, Ioannou Y, Eng C. Alpha-galactosidase A deficiency: Fabry disease. In: Scriver C, Beaudet A, Sly W, et al, eds. The metabolic and molecular bases of inherited disease. New York: McGraw Hill, 2001:3733-3774
52. Cable WJ, Kolodny EH, Adams RD. Fabry disease: impaired autonomic function. Neurology 1982;32:498-502.
53. Lao LM, Kumakiri M, Mima H, et al. The ultrastructural characteristics of eccrine sweat glands in a Fabry disease patient with hypohidrosis. J Dermatol Sci 1998;18:109-117 (Pubitemid 28518234)
54. Eng CM, Fletcher J, Wilcox WR, et al. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis 2007;30:184-192 (Pubitemid 46487999)
55. Beutler E, Grabowski G. Gaucher disease. In: Scriver C, Beaudet A, Sly W, et al, eds. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw- Hill, 2001:3635-3668
56. Wilcox WR. Lysosomal storage disorders: the need for better pediatric recognition and comprehensive care. J Pediatr 2004;144:S3-14.
57. Wraith JE, Clarke LA, Beck M, et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr 2004;144:581-588 (Pubitemid 38594757)
58. Kakkis ED, Muenzer J, Tiller GE, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 2001;344:182-188
59. Brooks DA. Alpha-L-iduronidase and enzyme replacement therapy for mucopolysaccharidosis I. Expert Opin Biol Ther 2002;2:967-976 (Pubitemid 36033261)
60. Cox-Brinkman J, Smeulders MJ, Hollak CE, et al. Restricted upper extremity range of motion in mucopolysaccharidosis type I: no response to one year of enzyme replacement therapy. J Inherit Metab Dis 2007;30:47-50.
61. Muenzer J, Gucsavas-Calikoglu M, McCandless SE, et al. A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Mol Genet Metab 2007;90:329-337 (Pubitemid 46241902)
62. Muenzer J, Wraith JE, Beck M, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 2006;8:465-473 (Pubitemid 44239134)
63. Wraith JE, Scarpa M, Beck M, et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr 2007;167:267-277
64. Harmatz P, Giugliani R, Schwartz I, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr 2006;148:533-539 (Pubitemid 44419350)
65. Harmatz P, Whitley CB, Waber L, et al. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr 2004;144:574-580 (Pubitemid 38594756)
66. Brady RO. Enzyme replacement for lysosomal diseases. Annu Rev Med 2006;57:283-296
67. Desnick RJ. Enzyme replacement and enhancement therapies for lysosomal diseases. J Inherit Metab Dis 2004;27:385-410. (Pubitemid 38756323)
68. Weinreb NJ, Charrow J, Andersson HC, et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 2002;113:112-119 (Pubitemid 34804747)
69. Rohrbach M, Clarke JT. Treatment of lysosomal storage disorders: progress with enzyme replacement therapy. Drugs 2007;67:2697-2716 (Pubitemid 350224380)
70. Kaplan P, Mazur A, Manor O, et al. Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase. J Pediatr 1996;129:149-153 (Pubitemid 26277260)
71. Wraith JE. Limitations of enzyme replacement therapy: current and future. J Inherit Metab Dis 2006;29:442-447 (Pubitemid 43880649)
72. Banikazemi M, Bultas J, Waldek S, et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 2007;146:77-86. (Pubitemid 351640010)
73. Wilcox WR, Banikazemi M, Guffon N, et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 2004;75:65-74. (Pubitemid 38756338)
74. Di Ferrante N, Nichols BL, Donnelly PV, et al. Induced degradation of glycosaminoglycans in Hurler's and Hunter's syndromes by plasma infusion. Proc Natl Acad Sci USA 1971;68:303-307
75. Knudson AG Jr, Di Ferrante N, Curtis JE. Effect of leukocyte transfusion in a child with type II mucopolysaccharidosis. Proc Natl Acad Sci USA 1971;68:1738-1741
76. Aldenhoven M, Boelens JJ, de Koning TJ. The clinical outcome of Hurler syndrome after stem cell transplantation. Biol Blood Marrow Transplant 2008;14:485-498
77. Peters C, Steward CG. Hematopoietic cell transplantation for inherited metabolic diseases: an overview of outcomes and practice guidelines. Bone Marrow Transplant 2003;31:229-239 (Pubitemid 36336225)
78. Krivit W. Allogeneic stem cell transplantation for the treatment of lysosomal and peroxisomal metabolic diseases. Springer Semin Immunopathol 2004;26:119-132 (Pubitemid 40021961)
79. Boelens JJ. Trends in haematopoietic cell transplantation for inborn errors of metabolism. J Inherit Metab Dis 2006;29:413-420 (Pubitemid 43880644)
80. Prasad VK, Kurtzberg J. Emerging trends in transplantation of inherited metabolic diseases. Bone Marrow Transplant 2008;41:99-108. (Pubitemid 351188906)
81. Meikle PJ, Hopwood JJ. Lysosomal storage disorders: emerging therapeutic options require early diagnosis. Eur J Pediatr 2003;162:S34-7.
82. Weinreb NJ, Barranger JA, Charrow J, et al. Guidance on the use of miglustat for treating patients with type 1 Gaucher disease. Am J Hematol 2005;80:223-229 (Pubitemid 41579546)